MedWatch

Novo still expecting EU Wegovy approval around the New Year

Before the turn of the year, Novo Nordisk predicts it will have received marketing approval for its obesity drug Wegovy in Europe.

Photo: Novo Nordisk / PR

There is still hope that obesity treatment Wegovy will be authorized for the European market before the end of the year.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs